ACADIA Pharmaceuticals Inc. (ACAD) Nears Key Phase 3 Readout in Prader-Willi Syndrome

In this article, we will be taking a look at the 11 Best Performing Biotech Stocks So Far in 2025. ACADIA Pharmaceuticals Inc. stands second among them. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is a biopharmaceutical company that focuses on therapies for central nervous system disorders and rare diseases. Its key approved products include NUPLAZID for hallucinations and delusions in Parkinson’s disease psychosis, and DAYBUE for Rett syndrome. Both of these products have seen growing commercial traction. ...